```
L1                STRUCTURE UPLOADED
L2              3 S L1 SSS SAM
L3             37 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007
L4             82 S L3
L5              2 S L4 AND ANGIOGENESIS (5W) INHIBIT?
L6              2 S L4 AND ANGIOGENESIS
L7              2 S L5 AND L6

=> d his

     (FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
L1                STRUCTURE UPLOADED
L2              3 S L1 SSS SAM
L3             37 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007
L4             82 S L3
L5              2 S L4 AND ANGIOGENESIS (5W) INHIBIT?
L6              2 S L4 AND ANGIOGENESIS
L7              2 S L5 AND L6
```

Copy for Sessing

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:sssptau183lec

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  MAR 15   WPIDS/WPIX enhanced with new FRAGHITSTR display format
 NEWS  3  MAR 16   CASREACT coverage extended
 NEWS  4  MAR 20   MARPAT now updated daily
 NEWS  5  MAR 22   LWPI reloaded
 NEWS  6  MAR 30   RDISCLOSURE reloaded with enhancements
 NEWS  7  APR 02   JICST-EPLUS removed from database clusters and STN
 NEWS  8  APR 30   GENBANK reloaded and enhanced with Genome Project ID field
 NEWS  9  APR 30   CHEMCATS enhanced with 1.2 million new records
 NEWS 10  APR 30   CA/CAplus enhanced with 1870-1889 U.S. patent records
 NEWS 11  APR 30   INPADOC replaced by INPADOCDB on STN
 NEWS 12  MAY 01   New CAS web site launched
 NEWS 13  MAY 08   CA/CAplus Indian patent publication number format defined
 NEWS 14  MAY 14   RDISCLOSURE on STN Easy enhanced with new search and display
                   fields
 NEWS 15  MAY 21   BIOSIS reloaded and enhanced with archival data
 NEWS 16  MAY 21   TOXCENTER enhanced with BIOSIS reload
 NEWS 17  MAY 21   CA/CAplus enhanced with additional kind codes for German
                   patents
 NEWS 18  MAY 22   CA/CAplus enhanced with IPC reclassification in Japanese
                   patents
 NEWS 19  JUN 27   CA/CAplus enhanced with pre-1967 CAS Registry Numbers
 NEWS 20  JUN 29   STN Viewer now available
 NEWS 21  JUN 29   STN Express, Version 8.2, now available
 NEWS 22  JUL 02   LEMBASE coverage updated
 NEWS 23  JUL 02   LMEDLINE coverage updated
 NEWS 24  JUL 02   SCISEARCH enhanced with complete author names
 NEWS 25  JUL 02   CHEMCATS accession numbers revised
 NEWS 26  JUL 02   CA/CAplus enhanced with utility model patents from China
 NEWS 27  JUL 16   CAplus enhanced with French and German abstracts
 NEWS 28  JUL 18   CA/CAplus patent coverage enhanced
 NEWS 29  JUL 26   USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS 30  JUL 30   USGENE now available on STN

 NEWS EXPRESS  29 JUNE 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
```

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6
DICTIONARY FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading A:\10-520580-R1-D'Oosterlynck et al...str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 22:27:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 22:27:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72 TO ITERATE

100.0% PROCESSED 72 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.01

L3 37 SEA SSS FUL L1

=> d scan

L3 37 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Acetonitrile, [(2S,3R,4S,6R)-3,4-bis(benzoyloxy)-6-(β-D-glucopyranosyloxy)-2-hydroxycyclohexylidene]-, (2Z)- (9CI)
MF C28 H29 N O11



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.55 172.76

FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 3 Aug 2007 (20070803/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> d his

     (FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
L1              STRUCTURE UPLOADED
L2            3 S L1 SSS SAM
L3           37 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007

=> s l3
L4           82 L3

=> s l4 and angiogenesis (5w) inhibit?
         39681 ANGIOGENESIS
       1948048 INHIBIT?
         12346 ANGIOGENESIS (5W) INHIBIT?
L5           2 L4 AND ANGIOGENESIS (5W) INHIBIT?

=> d l5 ed ibib abd hitstr 1-2
'ABD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS
```

```
IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):e3nd
'E3ND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS
```

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):abs

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
GI



I

AB Compds. having the general formula I-d-L-e-Y were claimed, wherein A nd B are independently H, CN, halogen, N3, substituted oxime, imine,

carboxylate, amide, alkyl, haloalkyl, cycloalkyl, acyloalkenyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxyaryl, heterocycle, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, aryloxy, acyloxy, oxy-heterocycle, alkylthio, cycloalkylthio, acylthio, thio-heterocycle, alkylamino, heterocyclic amino, hydroxyalkylamino, mercaptoalkylamino, alkynylamino, alkynylamino, acylamino, thioacylamino; A and B together form homo-cyclic or heterocyclic; T1-T5 are independently C, O, N; R1-R5 are independently H, CN, halogen, N3, OH, amino, carboxyl, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, substituted amino, substituted thio; S1-S5 are independently H, CN, halogen, carboxyl, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, aryloxy, acyloxy, oxy-heterocycle, substituted thio; n is 0-2; d represents a moiety for the attachment of X and L, which replaces any one of the substituents R1-R5 and S1-S5; L is a linker consisting of a covalent bond, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heteroalkyl, cyclo-heteroalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; e represents a moiety for the attachment of Y and L; Y is substituted heterocycle. This invention relates to the preparation of biol. active sugars such as monosaccharides and disaccharides having some degree of structural similarity with the simmondsin scaffold (no data). Compds. of the invention and tangeritin, a com. known angiogenesis inhibitor, are compared in their angiogenesis-inhibiting activity in vitro towards VEGF (Vascular Endothelial Growth Factor) stimulated angiogenesis (no data). Compds. of the invention are able to: (i) inhibit VEGF- and basic fibroblast growth factor-induced human endothelial cells proliferation, [ii] inhibit VEGF-induced in vitro tube formation by human micro-vascular endothelial cells in 3-dimensional fibrin matrixes, (iii) inhibit the ex vivo outgrowth of tube-like structures of endothelial cells from fetal mouse metacarpal, and (iv) inhibit in vivo neovascularization of matrigel chambers in mice (no data). The presence or absence of estrogen-like activity in the compds. of the invention is reported (no data).

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AB The present invention relates to the use of an active component derived from jojoba, and in particular a simmondsin, stereoisomeric forms, racemic mixts., metabolites, pharmaceutically acceptable esters or salts thereof, or mixts. thereof for the manufacture of a medicament for inhibiting angiogenesis and for the manufacture of a medicament for treating angiogenesis-related diseases. The present invention further relates to pharmaceutical compns. for inhibiting angiogenesis or for treating angiogenesis-related diseases in humans or animals and to methods for inhibiting angiogenesis and for treating angiogenesis-related diseases in humans or animals.

=> d his

(FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007)

FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
L1 STRUCTURE UPLOADED
L2 3 S L1 SSS SAM
L3 37 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007
L4 82 S L3
L5 2 S L4 AND ANGIOGENESIS (5W) INHIBIT?

=> d l5 ed ibib abs hitstr 1-2

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ED Entered STN: 18 Jan 2006
ACCESSION NUMBER: 2006:46765 CAPLUS
DOCUMENT NUMBER: 144:108546
TITLE: Preparation of monosaccharides and disaccharides simmondsin analogs as antitumor agents and angiogenesis inhibitors in study of drug discovery
INVENTOR(S): Van der Eycken, Johan
PATENT ASSIGNEE(S): Universiteit Gent, Belg.
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1616874	A1	20060118	EP 2004-447176	20040714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006005142	A2	20060119	WO 2005-BE114	20050713
WO 2006005142	A3	20060824		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2004-447176 A 20040714
OTHER SOURCE(S): MARPAT 144:108546
GI



I

AB Compds. having the general formula I-d-L-e-Y were claimed, wherein A nd B are independently H, CN, halogen, N3, substituted oxime, imine, carboxylate, amide, alkyl, haloalkyl, cycloalkyl, acyloalkenyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxyaryl, heterocycle, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, aryloxy, acyloxy, oxy-heterocycle, alkylthio,

cycloalkylthio, acylthio, thio-heterocycle, alkylamino, heterocyclic amino, hydroxyalkylamino, mercaptoalkylamino, alkynylamino, alkynylamino, acylamino, thioacylamino; A and B together form homo-cyclic or heterocyclic; T1-T5 are independently C, O, N; R1-R5 are independently H, CN, halogen, N3, OH, amino, carboxyl, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, substituted amino, substituted thio; S1-S5 are independently H, CN, halogen, carboxyl, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, aryloxy, acyloxy, oxy-heterocycle, substituted thio; n is 0-2; d represents a moiety for the attachment of X and L, which replaces any one of the substituents R1-R5 and S1-S5; L is a linker consisting of a covalent bond, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heteroalkyl, cyclo-heteroalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; e represents a moiety for the attachment of Y and L; Y is substituted heterocycle. This invention relates to the preparation of biol. active sugars such as monosaccharides and disaccharides having some degree of structural similarity with the simmondsin scaffold (no data). Compds. of the invention and tangeritin, a com. known angiogenesis inhibitor, are compared in their angiogenesis-inhibiting activity in vitro towards VEGF (Vascular Endothelial Growth Factor) stimulated angiogenesis (no data). Compds. of the invention are able to: (i) inhibit VEGF- and basic fibroblast growth factor-induced human endothelial cells proliferation, [ii] inhibit VEGF-induced in vitro tube formation by human micro-vascular endothelial cells in 3-dimensional fibrin matrixes, (iii) inhibit the ex vivo outgrowth of tube-like structures of endothelial cells from fetal mouse metacarpal, and (iv) inhibit in vivo neovascularization of matrigel chambers in mice (no data). The presence or absence of estrogen-like activity in the compds. of the invention is reported (no data).

IT 51771-52-9DP, Simmondsin, analogs
RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of monosaccharides and disaccharides simmondsin analogs as antitumor agents with potent angiogenesisinhibiting activity in study of drug discovery)

RN 51771-52-9 CAPLUS

CN Acetonitrile, [(2S,3R,4S,6R)-6-(β-D-glucopyranosyloxy)-2-hydroxy-3,4-dimethoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ED Entered STN: 18 Jan 2004
ACCESSION NUMBER: 2004:41294 CAPLUS
DOCUMENT NUMBER: 140:99578
TITLE: Simmondsin for use as an angiogenesis inhibitor
INVENTOR(S): D'oosterlynck, Andre; Raes, Stefaan
PATENT ASSIGNEE(S): Belg.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004746	A1	20040115	WO 2003-EP7270	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BE 1015023	A3	20040803	BE 2002-428	20020708
AU 2003246395	A1	20040123	AU 2003-246395	20030707
EP 1526862	A1	20050504	EP 2003-762641	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006088613	A1	20060427	US 2005-520580	20050426
PRIORITY APPLN. INFO.:			BE 2002-428 A	20020708
			WO 2003-EP7270 W	20030707

OTHER SOURCE(S): MARPAT 140:99578

AB The present invention relates to the use of an active component derived from jojoba, and in particular a simmondsin, stereoisomeric forms, racemic mixts., metabolites, pharmaceutically acceptable esters or salts thereof, or mixts. thereof for the manufacture of a medicament for inhibiting angiogenesis and for the manufacture of a medicament for treating angiogenesis-related diseases. The present invention further relates to pharmaceutical compns. for inhibiting angiogenesis or for treating angiogenesis-related diseases in humans or animals and to methods for inhibiting angiogenesis and for treating angiogenesis-related diseases in humans or animals.

IT 51771-52-9DP, Simmondsin, analogs 51771-52-9P, Simmondsin 135074-86-1P 135105-75-8P 179233-92-2P 644975-71-3P 644975-72-4P 644975-73-5P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(simmondsin for use as an angiogenesis inhibitor)

RN 51771-52-9 CAPLUS
CN Acetonitrile, [(2S,3R,4S,6R)-6-(β-D-glucopyranosyloxy)-2-hydroxy-3,4-dimethoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 51771-52-9 CAPLUS
CN Acetonitrile, [(2S,3R,4S,6R)-6-(β-D-glucopyranosyloxy)-2-hydroxy-3,4-dimethoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 135074-86-1 CAPLUS
CN Acetonitrile, [(2S,3S,4S,6R)-6-(β-D-glucopyranosyloxy)-2,3,4-trihydroxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 135105-75-8 CAPLUS
CN Acetonitrile, [(2S,3R,4S,5R)-6-(β-D-glucopyranosyloxy)-2,4-dihydroxy-3-methoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 179233-92-2 CAPLUS
CN Acetonitrile, [(2S,3R,4S,6R)-6-(β-D-glucopyranosyloxy)-2,3-dihydroxy-4-methoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 644975-71-3 CAPLUS
CN Acetonitrile, [(2S,3R,4S,6R)-2,3-dihydroxy-6-[[2-O-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-β-D-glucopyranosyl]oxy]-4-methoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 644975-72-4 CAPLUS
CN Acetonitrile, [(2S,3S,4S,6R)-2,4-dihydroxy-6-[[2-O-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-β-D-glucopyranosyl]oxy]-3-methoxycyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 644975-73-5 CAPLUS
CN Acetonitrile, [(2S,3S,4S,6R)-2,3,4-trihydroxy-6-[[2-O-[3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]-β-D-glucopyranosyl]oxy]cyclohexylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
L1             STRUCTURE UPLOADED
L2               3 S L1 SSS SAM
L3              37 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007
L4              82 S L3
L5               2 S L4 AND ANGIOGENESIS (5W) INHIBIT?

=> s l4 and angiogenesis
         39681 ANGIOGENESIS
L6               2 L4 AND ANGIOGENESIS

=> s l5 and l6
L7               2 L5 AND L6

=> d his

     (FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
L1             STRUCTURE UPLOADED
L2               3 S L1 SSS SAM
L3              37 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 22:28:11 ON 05 AUG 2007
L4              82 S L3
L5               2 S L4 AND ANGIOGENESIS (5W) INHIBIT?
L6               2 S L4 AND ANGIOGENESIS
L7               2 S L5 AND L6

=> d his

     (FILE 'HOME' ENTERED AT 22:26:45 ON 05 AUG 2007)

     FILE 'REGISTRY' ENTERED AT 22:26:56 ON 05 AUG 2007
```

PALM Intranet

Application Number [ ] Submit

IDS Flag Clearance for Application 10520580

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Last Modified	Reviewer
Update					